NDA 205739 · Vifor Pharma
Veltassa
Patiromer Sorbitex Calcium · Oral · Potassium Binder
NovelLast checked: Nov 20, 2026Latest source record: Oct 2, 2023 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2015
Oct 21, 2015
Approved uses
3
Original approval plus efficacy supplements
Registered trials
0
0 Phase 3, 0 recruiting
FAERS reports
13,806
6,761 serious, 2,126 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
From the label in effect Jan 31, 2025.
Veltassa is indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older. Limitation of Use: Veltassa should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action [see Clinical Pharmacology (12.2) ] . Veltassa is a potassium binder indicated for the treatment of hyperkalemia in adults and pediatric patients ages 12 years and older. ( 1 ) Limitation of Use Veltassa should not be used as an emergency treatment for life-threatening hyperkalemia because of its delayed onset of action. ( 1 )
Mechanism: Veltassa is a non-absorbed, cation exchange polymer that contains a calcium-sorbitol counterion. Veltassa increases fecal potassium excretion through binding of potassium in the lumen of the gastrointestinal tract. Binding of potassium reduces the concentration of free potassium in the gastrointestinal lumen, resulting in a reduction of serum potassium levels.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Oct 2, 2023 Supplement 38 · Efficacy Label
- May 2, 2018 Supplement 16 · Efficacy LetterLabel
- Oct 21, 2015 Original approval · Type 1 - New Molecular Entity NovelLabelReviewLetter
4 products under this application
- VELTASSA · PATIROMER SORBITEX CALCIUM EQ 25.2GM BASE/PACKET · POWDER, ORAL · Discontinued
- VELTASSA · PATIROMER SORBITEX CALCIUM EQ 8.4GM BASE/PACKET · POWDER, ORAL · Prescription
- VELTASSA · PATIROMER SORBITEX CALCIUM EQ 1GM BASE/PACKET · POWDER, ORAL · Prescription
- VELTASSA · PATIROMER SORBITEX CALCIUM EQ 16.8GM BASE/PACKET · POWDER, ORAL · Prescription
Clinical trials
Interventional ClinicalTrials.gov studies with "Patiromer Sorbitex" as an intervention, any sponsor and status, largest first.
No registered drug trials name this ingredient.
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
- constipation2,146
- death1,832
- diarrhoea1,296
- hospitalisation980
- off label use941
- blood potassium increased802
- nausea713
- drug dose omission672
- malaise584
- abdominal discomfort541
- inappropriate schedule of drug administration461
- vomiting450
FAERS reports by year
By the date FDA received the report.
View as table
| Year | Reports |
|---|---|
| 2016 | 3,462 |
| 2017 | 4,594 |
| 2018 | 1,774 |
| 2019 | 1,327 |
| 2020 | 896 |
| 2021 | 569 |
| 2022 | 313 |
| 2023 | 192 |
| 2024 | 191 |
| 2025 | 318 |
| 2026 | 170 |
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Part D: Veltassa (Patiromer Calcium Sorbitex)
2024 spending
$175M
Beneficiaries
52,133
163,389 claims
Per beneficiary
$3,358
$34.14 per unit
View as table
| Year | Spending |
|---|---|
| 2020 | $111,516,027 |
| 2021 | $105,568,566 |
| 2022 | $110,617,058 |
| 2023 | $153,775,939 |
| 2024 | $175,068,084 |
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Randomised, blinded, cross-over evaluation of the palatability of and preference for different potassium binders in participants with chronic hyperkalaemia in the USA, Canada and Europe: the APPETIZE study.
Wheeler DC, Søndergaard H, Gwynn C, et al. · BMJ Open 2024 · Clinical Trial, Phase IV, Randomized Controlled Trial
- Therapeutic update on oral potassium exchange resin use in chronic kidney disease patients: a systematic review of randomized controlled clinical trials.
Gruver J, Al-Makki A, Shepler B · J Pharm Pharm Sci 2023 · Systematic Review
Sponsor: Vifor Pharma
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.